Researchers from Fochon Biosciences Ltd. have reported the discovery and preclinical evaluation of a novel second-generation B-cell lymphoma 2 (BCL2) inhibitor, FCN-683, being developed for the treatment of B-cell malignancies. FCN-683 showed the ability to potently and selectively inhibit both wild-type BCL2 (IC50=0.11 nM) and multiple clinically relevant venetoclax-resistant mutants, including G101V, D103E/V/Y, F104L, A113G, R129L and V156D.
Salarius Pharmaceuticals Inc. has completed two GLP toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings reported. These results will be included in an IND application that the company plans to submit to the FDA this quarter.
A novel bispecific immunotherapy developed by Roche AG to target pancreatic cancer showed promising results combined with radiation therapy in preclinical trials carried out at the University of Colorado.
A heart-protective cardiac myosin inhibitor and two biologics – one for a type of non-Hodgkin lymphoma and another for an inflammatory skin condition – were among the therapies recommended for approval by the EMA’s Committee for Medicinal Products for Human Use this week.
The U.S. FDA’s Oncologic Drugs Advisory Committee has recommended by a wide majority that the PARP inhibitor Lynparza (olaparib) in a combination therapy for treating prostate cancer should be restricted to only patients whose tumors have a BRCA mutation.
KRAS Q61H mutation has been found in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small-cell lung cancer (NSCLC) among other solid tumors. In healthy cells, RAS proteins switch between ON and OFF states during signal transduction, but in cancer, mutations in RAS genes or regulators install RAS proteins in ON state permanently.
Researchers from Abbvie Inc. recently presented the discovery and preclinical evaluation of a novel CD19-targeting glucocorticoid receptor modulator (GRM) agonist antibody-drug conjugate (ADC), ABBV-319, being developed for the treatment of B-cell malignancies.
Cyclin-dependent kinase 8 (CDK8) is implicated in both transcription and cellular response to environmental stress signals. Due to its association with the complex that sustains cell proliferation and viability, and its role in cancer cell stress response to radiotherapy and chemotherapy, CDK8 is considered a target to watch in cancer therapy.
RSS
